<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

OUR RESOURCES

CASE STUDY

CMR Surgical prepares for commercialisation on the back of $100m Series B

Key findings: In June 2018, surgical robotics company CMR Surgical raised $...

Read More

Endomag secures £8m Series C for scale up

Key learnings: UK and US-based Endomag raised £8 million through its Series...

Read More

PharmaKrysto kickstarts cystinuria drug development programme with licensing deal

Key learnings: PharmaKrysto has signed a licensing deal with Rutgers Univer...

Read More
View More

EXPERT INSIGHT

Commercialise and partner successfully in Europe and the Middle East

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Key challenges to scaling up early-stage investment in the life sciences

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More
View More

INVESTORVIEW

Investorview: Ingredients for growth in life sciences investment

Industrifonden is an evergreen venture capital fund with headquarters in St...

Read More

Investorview: Why people are key in life science investments

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More

Investorview: Plugging knowledge gaps to accelerate life science start-up development

Venture capital firm Hadean Ventures closed its first fund at the end of 20...

Read More
View More

LSX REPORT

Key challenges to scaling up early-stage investment in the life sciences

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

Reviewing life sciences deal trends

For the first seven months of this year (to July) our Deal Watch analysis o...

Read More
View More

WHITE PAPER

Infographic: C-suite challenges in life sciences 2018

In early 2017, LSX, formerly Biotech and Money, published the inaugural Inv...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

Medius Deal Watch July-August 2018

This issue of Deal Watch focuses on deal activities during the months of Ju...

Read More
View More

VIDEO

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with HemoGenyx's Vladislav Sandler

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More
View More

EVENT

The value potential of blockchain in healthcare: Q&A with Patientory’s Chrissa McFarlane

More than nine in 10 (91%) health executive respondents believe blockchain ...

Read More

Growing opportunities in cannabinoid-based treatments: Q&A with Casa Verde Capital's Karan Wadhera

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Realising the potential of cannabinoid-related therapies: Q&A with Artelo Biosciences’ Greg Gorgas

On 10-11 October 2018, investors, industry stakeholders, and senior executi...

Read More
View More

WEBINAR

Advanced therapies: Gaining market access in a challenging European environment

Listen to the final session in Phacilitate and LSX's (formerly known as Bio...

Read More

Overcoming commercialisation challenges in advanced therapies

Learn more about the commercialisation of advanced therapies in the on-dema...

Read More

Why whistleblowing should be a boardroom issue in life sciences

On-demand webinar now available New EU-wide whistleblowing regulations have...

Read More
View More